Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. News
  7. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : Finds Potential Treatment Gap Among Spasticity Patients in US

06/11/2021 | 06:16am EDT


ę MT Newswires 2021
All news about IPSEN
08/02Top Midday Gainers
MT
08/02EXICURE : Working With Ipsen to Develop Potential Therapeutics for Neurodegenera..
MT
08/02IPSEN : Exicure to Develop Treatment for Neurodegenerative Illnesses
MT
08/02IPSEN : Exicure collaboration-2 August 2021
PU
08/02PRESS RELEASE : Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kaliniche..
DJ
08/02Ipsen and Exicure Enters into Exclusive Collaboration Targeting Rare Neurodeg..
CI
07/30IPSEN : Exceeding again our CSR-based targets
PU
07/29IPSEN : delivers strong H1 2021 results and upgrades full-year...
PU
07/29Ipsen S.A. Raises Sales Guidance for the Fiscal Year 2021
CI
07/28GLOBAL MARKETS LIVE : Apple, Alphabet, Facebook, Pfizer, McDonald's...
More news
Financials
Sales 2021 2 782 M 3 302 M 3 302 M
Net income 2021 572 M 680 M 680 M
Net Debt 2021 70,7 M 83,9 M 83,9 M
P/E ratio 2021 13,1x
Yield 2021 1,15%
Capitalization 7 480 M 8 890 M 8 880 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,58x
Nbr of Employees 5 700
Free-Float 41,9%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 90,68 €
Average target price 94,85 €
Spread / Average Target 4,59%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN33.55%8 890
JOHNSON & JOHNSON9.46%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.19.42%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY46.06%221 348